Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen C Munger

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis and Related Disorders|March 17, 2020
Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancyKathleen C Munger, Lawrence M Samkoff
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 2, 2021
The impact of cognitive rehabilitation on quality of life in multiple sclerosis: A pilot studyKathleen C Munger, Amy Pacos Martinez, Megan H Hyland
The Neurohospitalist|May 7, 2020
Difficult Discharges to Skilled Nursing Facilities Attributed to Multiple Sclerosis Medications: An Observational StudyKathleen C Munger, Benjamin P George, Lawrence M Samkoff, et al.
Frontiers in Immunology|March 3, 2020
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal AntibodiesDavid Baker, Liaqat Ali, Gauri Saxena, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis and Related Disorders|March 17, 2020
Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancyKathleen C Munger, Lawrence M Samkoff
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 2, 2021
The impact of cognitive rehabilitation on quality of life in multiple sclerosis: A pilot studyKathleen C Munger, Amy Pacos Martinez, Megan H Hyland
The Neurohospitalist|May 7, 2020
Difficult Discharges to Skilled Nursing Facilities Attributed to Multiple Sclerosis Medications: An Observational StudyKathleen C Munger, Benjamin P George, Lawrence M Samkoff, et al.
Frontiers in Immunology|March 3, 2020
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal AntibodiesDavid Baker, Liaqat Ali, Gauri Saxena, et al.
Pageof 1